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A REVIEW OF BACTERIOPHAGE TREATMENTS 
FOR PSEUDOMONAS AERUGINOSA INFECTIONS 
 
 
KYLE HAGEN 
 
ABSTRACT 
 With the spread of antibiotic resistance, alternative treatment methods for 
bacterial pathogens are needed. Pseudomonas aeruginosa is a Gram negative, 
opportunistic pathogen that is a common cause of healthcare associated 
infections and is listed as a critical priority for research and development of 
treatments by the Centers for Disease Control and Prevention. P. aeruginosa 
poses an increased risk to patients within the surgical or intensive care unit, 
patients with indwelling catheters, cystic fibrosis, and burn wound victims. With a 
paucity of antibiotics in the pipeline for Gram negative bacteria, phage therapy 
has reemerged as a potential treatment option. Bacteriophages were first 
discovered in 1917 by Felix d’Herelle, but by the end of World War II, they were 
all but forgotten in favor of antibiotics. Eastern European countries and the 
former Soviet Union continued to develop phage therapy since its discovery, but 
studies were not on par with today’s standards. Recently the idea of phage 
therapy has reemerged in the Western world due to antibiotic resistance. In vitro 
and in vivo studies have shown that bacteriophages are easily isolated from the 
environment, with P. aeruginosa specific phages commonly found in hospital 
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waste water and in sewage. Phage therapy has shown to be very effective at 
treating planktonic and biofilm forms of antibiotic resistant P. aeruginosa in vitro 
and in vivo. In humans, clinical trials are limited but phage therapy has 
successfully treated chronic otitis infections caused by P. aeruginosa and other 
studies have demonstrated the safety of phage therapy, reporting mild, if any, 
adverse effects. Bacteriophages may also synergize with several antibiotics, 
suggesting it may be beneficial to use them in conjunction to treat difficult or 
chronic infections. Additionally, P. aeruginosa bacteriophages may be beneficial 
in prophylactic treatment as well. When phages were combined with chlorine, a 
significant decrease in P. aeruginosa counts in chronic biofilms was observed, 
while also reducing its ability to form new biofilms. Similar results were noted 
when phages were applied to the lumen of catheters. These early results are 
promising for the future, but there are many steps that must be taken before 
starting new clinical trials and the widespread use of phage therapy begins. 
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 1 
INTRODUCTION 
 
The emergence and spread of antibiotic resistance is currently one of the 
top public health threats extending across the globe.1 There is fear that we are 
on the path towards entering a “post-antibiotic era,” where infections can no 
longer be effectively treated by our current arsenal of antibiotics.1 In addition to 
bacteria developing resistance against our current arsenal of antibiotics, the 
pipeline for research and discovery of novel antibiotics has largely declined over 
the past several decades, instead focusing on optimization of current 
treatments.1 The use and misuse of antibiotics, along with the lacking pipeline of 
novel antibiotics has led us to select for antibiotic-resistant and multidrug-
resistant pathogens (MDR).1 
 
There are six bacterial species known as the ‘ESKAPE pathogens’ that 
are opportunistic, antibiotic-resistant, and pose an increased threat to patients in 
a hospital setting.2 These six ESKAPE pathogens are as follows: Enterococcus 
faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter 
baumannii, Pseudomonas aeruginosa, and Enterobacter species.2 In the hospital 
setting where these pathogens are prevalent, there is an increased risk for 
healthcare-associated infections (HAI), with incidence of 5% in the United States, 
and 7.1% in Europe. Worse still is that in the developing world, HAI are even 
more prevalent, estimated at 15.5%.2 Particularly worrisome is the outlook for 
future treatments of Gram-negative bacteria, in which a review done in 2011 
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found that only 4 antibacterial agents had activity in vitro, 2 of which may have 
different targets, but none had novel mechanisms of action.3  
 
 The remainder of this thesis will focus on one specific Gram-negative 
ESKAPE pathogen, Pseudomonas aeruginosa. The World Health Organization 
(WHO) compiled a list of the twelve most important antibiotic-resistant bacteria 
for which they recommend new research and development is focused on finding 
new antibacterial treatments.4 The WHO labels carbapenem-resistant P. 
aeruginosa as “Priority 1: Critical,” and considered a serious threat by the 
Centers for Disease Control and Prevention (CDC).4,5  
  
 Penicillin was discovered in 1928 by Alexander Fleming, and was 
distributed to the public beginning in 1945.5 As time went on, additional 
antibiotics were discovered, and bacterial species developed resistance to these 
antibiotics (Figure 1). Notably, there was an emergence of pandrug-resistant 
(PDR) Pseudomonas species in 2004/2005. Pandrug-resistance is defined as 
“non-susceptibility to all agents in all antimicrobial categories.”6 
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Figure 1. Antibiotic Discovery and Resistance Timeline. Timeline from 1940s 
until 2011, indicating when drugs began to be used and when antibiotic-resistant 
strains were discovered. XDR refers to extensively drug resistant and PDR refers 
to pan drug-resistant. Figure adapted from CDC website.5 
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Pseudomonas aeruginosa 
 Pseudomonas aeruginosa is a dangerous opportunistic pathogen for 
hospital inpatients, especially for those who are immunocompromised, burn 
victims, in critical care, or have cystic fibrosis. One strain of P. aeruginosa, called 
PAO1 was genotyped and found to have one of the largest bacterial genomes, at 
6.3 million base pairs.7 It was proposed that this large genome may contribute to 
how P. aeruginosa can adapt and thrive in different environments, and gives it 
innate resistance to antibiotics.7 In a study published in 2016, incidents of HAIs 
were reported to the CDC from 2011-2014 and found P. aeruginosa to be the 6th 
most common, accounting for 7.3% of all HAIs.8 This is down from 7.5% and 5th 
most common from the previous collection of data occurring from 2009-2010.9 
According to the CDC, each year P. aeruginosa is the cause of an estimated 
51,000 HAIs, and more than 6000 of these are MDR, causing over 400 deaths.5 
In intensive care and surgical units, the prevalence of antibiotic-resistance 
compared to general inpatient is even higher.10 P. aeruginosa is responsible for 
many types of infections as shown in Table 1. 
 
 Pseudomonas aeruginosa has several important virulence factors that 
make it difficult to treat. Lectins are present on the outer membrane and are 
responsible for dissemination, biofilm formation and survival.11 In addition, lectins 
play a role in the severity of lung bacterial load and injury.11 Iron chelation via 
siderophores such as pyocyanin plays a role in establishing infections and in the 
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progression to becoming a chronic infection by interrupting normal ciliary function 
the respiratory tract of the host organism and damaging the host cells.11 
 
Table 1. Pseudomonas aeruginosa Infections. A list of infections caused by 
Pseudomonas aeruginosa and their routes and characteristics. Table adapted 
from Al-Wrafy et al. 2017.11 
 
 
 
Quorum sensing is used by the community of bacteria as a biofilm is forming to 
“talk” and adapt to metabolic demands.11 On the outer membrane of the cell wall 
of Gram-negative, including P. aeruginosa are lipopolysaccharides (LPS) as 
shown in Figure 2. LPS is responsible for several key interactions, such as 
structural integrity of biofilms, adhesion, and interactions with antibiotics.11 
Biofilms are formed when P. aeruginosa produces an extracellular matrix made 
of alginate and other exopolysaccharides.11 The ability to form a biofilm is one of 
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the most important virulence factors, due to its ability to protect P. aeruginosa by 
providing a physical barrier and preventing or slowing progression of antibiotics 
penetrating through the biofilm.11 Additionally, bacteria within the biofilm have 
lowered metabolic states, which antibiotics are less effective at killing.11  
 
 
 
Figure 2. Pseudomonas aeruginosa Cell Membrane Structure. Depicted are 
the cytoplasmic membrane, peptidoglycan layer, and outer membrane with efflux 
pump system. Figure taken from Livermore 2002.12  
 
 P. aeruginosa biofilms are often associated with more severe and difficult 
to treat infections. Biofilms are able to form on many different surfaces, such as 
sinks, contact lenses, catheters, ventilator tubes, humidifiers and the lungs of 
patients with cystic fibrosis.13,14 The lung epithelium in cystic fibrosis patients is a 
favorable environment for P. aeruginosa infections, and is the most common 
cause of respiratory failure in this patient population.15 With infection beginning in 
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early childhood, obtained through the environment and transmitted between 
people, 21% of those under the age of 1 develop infections.15  
By the age of 19, 80% of cystic fibrosis patients have developed chronic 
infections caused by P. aeruginosa.15,16 Recurrent infections are caused by the 
impaired mucociliary clearance and can extend into the lower respiratory tracts. 
Initially, the phenotype of P. aeruginosa is non-mucoid producing, but as the 
infections becomes chronic and the biofilm begins to form it transitions into 
mucoid producing colonies.15,17 Once the mucoid layer begins to form, it 
becomes extremely difficult to treat, and most P. aeruginosa infections in the 
cystic fibrosis are never fully treated.14 The continued use of antibiotics leads to 
selection of cells with increased antibiotic resistance, and heterogeneity within 
the biofilm colonies begins.14 At this point, there are multiple strains in each 
colony with varying susceptibility to antibiotics, and due to the mucus in the lungs 
of cystic fibrosis, it is difficult to achieve optimal concentrations of antibiotics at 
the target location.14 Additionally, there are persister cells that lie dormant and 
are highly resistant to antibiotics.16 However, it has been found that the virulence 
of P. aeruginosa is decreased at the expense of developing antibiotic 
resistance.17 It is proposed that the most effective way to handle P. aeruginosa in 
cystic fibrosis patients is to treat with antibiotics early and aggressively, to 
prevent it from reaching a chronic state.18 
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 There are currently several antibiotic options that have proven useful, 
however the high rates of resistance seen in P. aeruginosa means that often the 
wrong treatment is started prior to identifying the strains present.19 The dosages 
of current options for cystic fibrosis patients are shown in Table 2.  
 
There are several antibiotic families that can be used to treat P. 
aeruginosa infections including: Antipseudomonal penicillins, cephalosporins, 
aminoglycosides, monobactams, carbapenems and fluoroquinolones.19 The 
cephalosporin ceftazidime is the preferred antibiotic if the isolate is susceptible.19 
The fluoroquinolone levofloxacin has shown activity against biofilms, but has an 
increased risk for selecting for resistance compared to ciprofloxacin.19,20 It is 
believed that biofilms in chronic infections harbor hypermutator strains that are 
easily transformed into MDR strains after being selected for by antibiotic use.21,22  
 
Although it is unclear if the benefits outweigh the risks of antibiotic 
combination therapy, there have been 2 combinations with high synergy: 
ceftazidime-tobramycin, and piperacillin-tazobactam-tobramycin.19 Carbapenems 
such as imipenum have been reserved as a last line of defense for when P. 
aeruginosa is resistant to all other options.19 Unfortunately, the highly adaptive 
pathogen has been able to develop resistance against imipenum as well.19 
Mutations in porins such as OprD, which is an outer membrane protein causes  
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this resistance to imipenum, blocking its ability to travel across the cell 
membrane.22 OprD is co-regulated with an efflux pump, MexEF-OprN.22 
Decreased membrane permeability also confers resistance to aminoglycosides.12 
Generally, resistance to carbapenems and aminoglycosides is caused by 
acquiring drug resistance genes. On the other hand, point mutations can effect 
efflux pumps such as MexAB-OprM, MexCD-OprJ, MexEF-OprN, and confer 
resistance to fluoroquinolones and most β-lactams.22 If point mutations in genes 
regulating efflux channels are the cause of resistance, tobramycin and 
merepenem can still be used for treatment.22 However, when these antibiotic 
families are ineffective the last line of defense is to use colistin for 
treatment.12,23,24 Although colistin is an antibiotic that was mostly discontinued in 
the 1980’s due to nephrotoxicity, there has been a reemergence in it’s use and 
inhaled colistin has been successfully used to treat MDR P. aeruginosa that was 
not otherwise treatable with intravenous antibiotics.19 However, inhaled delivery 
of antibiotics for treating pneumonia caused by P. aeruginosa is not currently 
recommended.19 
 
 While most of P. aeruginosa strains are still susceptible to many 
antibiotics, the rate of MDR strains is rising in patients in intensive care units, or 
with cystic fibrosis patients.12 The increase in drug resistance over a 4 year 
period from 1996-2000 is visualized in Figure 3 and the increase in prevalence 
of MDR strains in the same time period are shown in Table 3.12 With the 
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increasing prevalence of MDR P. aeruginosa and paucity of new antibiotics in the 
pipeline for Gram-negative bacteria, it is time to investigate alternative options for 
treatment, such as bacteriophages.25 
 
 
 
Figure 3. Percent Resistance of P. aeruginosa, 1996-2000. Isolates from the 
United States were tested for resistance against 6 antibiotics, and there was a 
general upward trend in the percent resistant to each of the 6 antibiotics. Not all 
isolates were tested with all antibiotics. Figure adapted from Livermore 2002.12  
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Table 3. Multidrug Resistance of P. aeruginosa, 1996-2000. Isolates from the 
United States were tested for resistance against 6 antibiotics. There is an 8% 
increase in the number of isolates resistant to more than 3 of the tested 
antibiotics over the course of 4 years. Figure adapted from Livermore 2002.12  
 
 
 
 
Bacteriophages 
Bacteriophages are the most abundant organisms on earth, with more 
than 1032 bacteriophages on the planet, they outnumber bacteria 10-to-1.26 
Having co-evolved with bacteria for billions of years, there is a large variety in the 
morphology and genomes of bacteriophages (Table 4).26 Being that 
bacteriophages are ubiquitous in nature, and natural parasites to bacteria, it is 
reasonable to investigate them as a source for treating bacterial infections.  
 
Bacteriophages were first unknowingly discovered in 1896, when Ernest 
Hankin reported antibacterial activity against Vibrio cholera, however he is not 
credited with the true discovery. In 1915, Frederick Twort hypothesized viruses 
had antibacterial activity, but did not have the funding to pursue it further. In 
1917, Felix d’Herelle was the first to describe bacteriophages.27 
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Table 4. Bacteriophage Families. A description of the bacteriophage families. 
Table adapted from Hanlon 2007.26  
 
 
 
  Once discovered, d’Herelle initially did work in the laboratory to confirm 
phage therapy worked, but then went straight to clinical setting without first 
conducting clinical trials with appropriate placebo groups.28 Felix d’Herelle 
continued to develop the use of bacteriophages to treat infections, but in the 
1940s antibiotics were discovered. In 1934 there was a review of all the papers 
published on bacteriophages and their resulting conclusion was not in favor of 
phage therapy.28 Due to poor understanding of the nature of bacteriophages, and 
poorly conducted research, the Western world looked towards antibiotics as the 
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primary means for treating infections. There were additional problems from early 
phage research, such as poor stability or viability of the phage, exaggerated 
claims of effectiveness and failure to establish proof of efficacy.28 Ultimately, the 
therapeutic use of phages was essentially forgotten, but research continued in 
Eastern Europe and in the Soviet Union.26,29,30 Much of this continued research 
and development was published in Georgian and Ukrainian, however it has been 
argued that there were issues including poor experimental design, and lacking 
the proper controls.26 
 
 Potentially, language barriers slowed the research and development of 
phage therapy, but a resurgence began in the 1980s, with the first human trials 
beginning in the 2000s.28 Due to the increase in antibiotic-resistant and MDR 
bacterial pathogens in the last several decades, and a paucity of antibiotics with 
new mechanism of action in the pipeline, a non-antibiotic antibacterial method is 
a viable alternative.28 
 
Some advantages of phage therapy are that they are active against all 
types of bacteria, including those that are antibiotic resistant and MDR. Another 
advantage is the specificity of bacteriophages, generally they are only effective 
against one specific type of bacteria, and therefore do not affect others in the 
microbiota.28 Bacteriophages can be administered in smaller dosages compared 
to antibiotics, because the dose effectively increases at the location of the 
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infection as they multiply. Bacteriophages also have the capability to pass the 
blood brain barrier and to disrupt and prevent biofilm formation.28 Economically, 
phage therapy is also cheaper than antibiotic therapy.28 Some of the key 
differences between phage therapy and antibiotics are presented in Table 5.28 
The early work done in the former Soviet Union and Poland also showed that 
phage therapy has few mild adverse side effects, and this could be because 
humans are exposed to bacteriophages on a daily basis due to their ubiquitous 
nature.26,30 
 
Table 5. Comparison of Bacteriophages and Antibiotics. Comparing the 
targets, concentrations, side effects, bacterial resistance, and development of 
bacteriophages and antibiotics. Adapted from Sulakvelidze et al. 2001.28 
 
 
Bacteriophages Antibiotics 
Very specific, affecting only targeted 
bacterial species 
Antibiotics affect both the pathogenic 
bacteria and the normal microflora 
Replicate at the site of infection to 
increase concentration 
Metabolized and eliminated from the 
body, do not necessarily concentrate 
at infection site 
No serious side effects described Multiple side effects 
Phage-resistant bacteria are still 
susceptible to other phages 
Antibiotics select for resistance in 
targeted pathogens as well as those 
in the microflora 
Selection of new phages is quick, 
taking days to weeks 
Developing new antibiotic is slow and 
takes several years 
 
There are some bacteriophages that are better suited for phage therapy 
than others, and this is specific to their life cycles. There are two types of 
 16 
bacteriophage life cycles: the lytic cycle, also known as the virulent cycle, and the 
lysogenic cycle, also known as the temperate cycle.26 The lytic cycle results in 
the rapid death of the host organism. The lysogenic cycle instead has a 
quiescent stage in which the bacteriophage inserts its genome into the host 
genome, called the prophage.26 A lysogenic phage can exist as a prophage for 
an extended period and can be passed on through vertical transmission to host 
cell progeny. When the host cell undergoes a stressor, such as oxidative stress, 
the prophage is then expressed and the cycle converts into the lytic cycle.26 To 
begin the life cycle, a bacteriophage will attach to a bacterium via specific 
receptors on the cell surface, flagella, or pili.26 Next, bacteriophages inject their 
genome into the host cell, take over the metabolic machinery and produce 
progeny. The new bacteriophages have enzymes capable of lysing the host cell 
from the inside using holin and endolysin to create holes in the cell membrane 
and peptidoglycan layer, respectively.26 This allows for the release of the phage 
progeny able to begin the cycle again (Figure 4).26,31 For the purposes of phage 
therapy, the lytic cycle is most beneficial. This is because in the lysogenic cycle, 
the removal of the prophage is imprecise and can potentially cause unwanted 
horizontal gene transfer of bacterial toxins.26 Over 90% of bacteriophages are 
made up of 3 morphological families of Caudovirales, the Myoviridae, 
Siphoviridae, and Podoviridae (Figure 5). These families have dsDNA genomes, 
undergo the lytic lifecycle and are ideal for Pseudomonas aeruginosa.26,29,30,32  
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Figure 4. Bacteriophage Life Cycles. Lytic and Lysogenic life cycles of 
bacteriophages are shown here. Figure adapted from Harper and Enright 2011.33 
 
 
 
 
 
Figure 5. Caudovirale Morphologies. The 3 major morphological groups of the 
Caudovirales. Myoviridae have long, rigid contractile tails. Podoviridae have short 
noncontractile tails. Siphoviridae have long, flexible noncontractile tails. Figure 
adapted from Harper and Enright 2011.33 
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 Phage therapy is an ideal alternative to antibiotics because resistance to 
bacteriophages develops at a rate 10 times slower than resistance to 
antibiotics.34 P. aeruginosa that develops resistance to bacteriophages does so 
at the cost of their fitness, as they become less virulent.35 Additionally, compared 
to antibiotics there are many different phages that are easily isolated and may be 
effective via a different mechanism of infection to these bacteriophage-resistant 
strains. One study performed investigated aquatic sources near to a hospital for 
phage activity against clinical strains of ESKAPE pathogens. It was found that 
many aquatic sources harbor phages that have activity against P. aeruginosa, 
and the most effective phages are mainly found in waste water (Figure 6).36  
 
Another study compared the genome of 18 P. aeruginosa bacteriophages, 
and they found that there was a large range of diversity, with 55% of the open 
reading frames being novel.37 This is promising, as it suggests that there are 
many different bacteriophages that are easily isolated from the environment, and 
have a wide range of diversity.37 This allows for the treatment of P. aeruginosa 
infections even if phage resistance develops, because there will likely be another 
phage active against it.37 
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Figure 6. Phage Activity Heatplot Against ESKAPE Pathogens. Greyscale 
heatplot with white showing no phage activity against the clinical strains, and 
black showing activity against all clinical strains tested. Phages were obtained 
from 16 aquatic locations near a hospital in Aachen, Germany. E: Enterococcus 
faecium. S: Staphylococcus aureus. K: Klebsiella pneumoniae. A: Acinetobacter 
baumannii. P: Pseudomonas aeruginosa. E: Enterobacter species. Figure 
adapted from Latz et al. 2016.36 
 
Bacteriophages have several benefits compared to antibiotics. 
Bacteriophages only target the pathogen of interest, and normal gut microflora is 
not affected (Table 5). This avoids the potential of secondary pathogens arising 
post antibiotic treatment.26 Additionally, bacteriophages are effective against 
pathogens that are antibiotic-resistant or MDR.26 
   
 20 
Bacteriophages also have better penetration into biofilms compared to 
antibiotics, and can infect and lyse persister cells that standard antibiotics are 
unable to destroy.16 With each life cycle, bacteriophages amplify their 
concentration at the site of infection, while antibiotics are cleared and need 
multiple doses, and do not concentrate at the site of infection.33 
 
 However, phage therapy is not limited to this conventional use as there 
are many ways phages can be used. Phages can be combined into a cocktail of 
several phages to make phage resistance harder for the pathogen to achieve.2 
Phage therapy can also be used in conjunction with antibiotics.2 Phage therapy 
can be used prophylactically, possibly administered in surface disinfectant for 
hospital equipment.2 It’s also possible to engineer phages entirely, giving them 
ideal properties that are not found in nature.2 It is also possible to engineer lysis-
deficient phages or use phage enzymes that are used to lyse the bacteria.38,39 
The following will be a compilation of the studies performed using phage therapy 
against P. aeruginosa in a variety of infection types.  
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Specific Aims 
 The specific aims of this thesis are as follows: 
1. Review of the literature of phage therapy used to treat P. aeruginosa in 
vitro, in vivo, and in human clinical trials.  
2. Review literature regarding synergy between antibiotics and phage 
therapy in the treatment of P. aeruginosa.  
3. Review of other potential uses for phages against P. aeruginosa.  
4. Discuss the current problems facing phage therapy as a viable option 
and future directions.  
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PUBLISHED STUDIES 
 
 Treatment of P. aeruginosa via phage therapy has shown promising 
results in vitro, in vivo and in early clinical trials on humans.40 The remainder of 
this thesis will focus on the results of these studies and the efficacy of phage 
therapy, as well as discuss potential problems and future directions. 
 
In Vitro Studies 
A lytic bacteriophage called JHP was isolated from a sewage sample. JHP 
was found to be effective at reducing the growth of 9/12 strains of multi-drug 
resistant P. aeruginosa that were isolated from blood and wound swabs.41 The 
characteristics of JHP were also noted in this study. JHP is of the Siphoviridae 
family of phages, is most active at pH 7 and temperature 37°C, and can be 
stored at 4°C or -20°C.41 The latent period was found to be 25 minutes before 
producing an average of 433 new phages per host cell lysed.41 JHP was also 
shown to have activity against Enterobacteracae family members, giving it a 
broader range of activity, however it was not harmful to probiotic bacteria.41 
These are all important factors that make it a good potential candidate for phage 
therapy in humans.41 
 
P. aeruginosa has the ability to form biofilms on indwelling Foley 
catheters. A study by Fu et al. investigated if a bacteriophage called M4 phage 
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could be applied to a hydrogel-coated catheter to prevent biofilm formation of P. 
aeruginosa M4. Catheters were treated with a single phage or cocktail of phages 
before or immediately after the inoculation of the catheter with P. aeruginosa. 
The pretreated catheters had a 99% reduction in biofilm formation after 24 hours, 
and the post-treatment catheters also had significant reduction of biofilm 
formation.42 It was also found that applying additional M4 phage to the 
pretreatment group at the 24-hour mark decreased biofilm counts, while the 
remainder of the biofilms were deemed to be resistant to M4 phage.42 
 
 A second experiment was then conducted using a cocktail of M4 phage 
and 4 other phages that had the best activity against the M4-resistant P. 
aeruginosa that formed from the first experiment. The results of this experiment 
show that there was a 99.9% reduction in biofilm formation in the pretreated 
catheters.42 The cocktail pretreatment was also found to be more effective than 
the pretreated single phage therapy with an additional dose at the 24-hour mark. 
This study is important because it shows the importance of using multiple 
phages, and that they may be useful for prophylactic treatments on other 
surfaces.42 Another study isolated bacteriophage AZ1 from waste water which 
was used in monophage therapy against P. aeruginosa 2995. AZ1 was found to 
have a latency period of 33 minutes, and a burst size of 326 phage progeny per 
cell.43 AZ1 was able to decrease the concentration of cells in both the planktonic 
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and biofilm forms, but ultimately it was concluded that a cocktail of phages would 
be necessary to fully eradicate the pathogen.43  
 
The Liverpool Epidemic Strain (LES) is one of the most common cystic 
fibrosis associated P. aeruginosa strains found in the United Kingdom.44 LES is 
associated with increased mortality and morbidity. One study tested the efficacy 
of 7 bacteriophages against 84 isolates of LES.44 It was determined that the 
bacteriophages killed up to 98% of the LES isolates, with 2 of the isolates being 
resistant to all phages tested.44 However, the 2 multi-phage resistant strains were 
susceptible to antibiotics.44 The study selected 2 of the 7 bacteriophages with the 
largest host ranges to determine if they can be delivered via a nebulizer to the 
lower airways. The amounts of viable phage delivered via nebulizer were 
determined using 2 different nebulizers. With the AeroEclipse nebulizer, 15% of 
the original dose of bacteriophages were viable, and 12% were contained in 
particles small enough to reach the lower respiratory tracts.44 In comparison, 
Omron nebulizers were only able to deliver 1% of the original dose as viable 
bacteriophages.44 Another team attempted to create dry power inhalers using 
endotoxin-removed phage, ФKZ. ФKZ was lyophilized in lactose/lactoferrin 60 : 
40 w/w matrix to make the powders.45 Results showed that ФKZ retained activity 
in this powder form and could be aerosolized to treat lung infections.45 
Additionally, it was determined that the powder retained viable bacteriophages 
after being stored at either 4°C and 22°C for 3 months.45 
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A study was performed to screen for bacteriophages that can break apart 
the capsule of biofilm-forming mucoid strains of P. aeruginosa. Of the 4/21 
phages they discovered with capsule hydrolytic activity, one called PT-6 was 
chosen for additional investigation by Glonti et al. It was determined that PT-6 
has alginase activity, meaning it can break apart the biofilm of mucoid-producing 
strains of P. aeruginosa by hydrolyzing the exopolysaccharide.46 This is 
important because identifying phages with these properties may be beneficial to 
treating cystic fibrosis patients with acute and chronic P. aeruginosa infections.46 
 
 In chronic P. aeruginosa infections found in cystic fibrosis patients of 
greater than 2 years duration, there is reduced resistance to phages, while 
having an increased resistance to multiple antibiotics.47 However, this was not 
the case for infections lasting less than 2 years.47 Several lytic phages with 
activity against P. aeruginosa were evaluated to determine the amount of 
resistance (Figure 7). Isolates from patients with infections lasting over 2 years 
were used to infect Galleria mellonella, and reduced killing was noticed, with the 
possible explanation that the long-term adaptations resulted in a phenotype that 
is less virulent than wild-type strains of P. aeruginosa.47 
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Figure 7. Phage Resistance in Cystic Fibrosis P. aeruginosa Isolates.  
The phage resistance was tested for intermittent infections (1-23 months) and 
chronic infections (2-23 years) for 4 phage species: 14/1, PT7, KZ, and PNM. 
Chronic infections showed less phage resistance than intermittent infections. 
Figure adapted from Friman et al. 2013.47  
 
In Vivo Studies 
Using a murine burn model, a lethal infection of P. aeruginosa was applied 
to the burn wound and the mice were treated with a single dose of a cocktail 
containing three P. aeruginosa phages, through three different routes: 
intramuscular, subcutaneous, and intraperitoneal.48 The concentration of each 
phage in the cocktail was 108 Plaque-forming units (PFU). The results showed 
that a single dose significantly decreased the mortality levels of the mice. 
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Survival in the control group was at 6%, while treatment groups increased from 
22 to 87%.48 The group with 87% survival was administered the cocktail 
intraperitoneally. It was determined that phages administered intraperitoneally 
arrived to the target location earlier, and in higher concentrations, which indicates 
there is a benefit to determining the best method of delivery for each type of 
therapy.48  
 
A Galleria mellonella model was used to determine the efficacy of phage 
therapy against P. aeruginosa PAO1. G. mellonella was infected with either 10 or 
100 cells of PAO1.49 Several different multiplicities of infections (MOI) of 
bacteriophages were tested either 2 hours before infection (prevention), or 2 
hours post infection (treatment), and were administered intravenously. Survival 
rates at 24 hours were tracked. The results indicate that prophylactic phage 
therapy is more effective than treatment after the infection has begun.49 
Additionally, it was shown that higher MOI was more effective at keeping  
G. mellonella alive for longer periods.49 
 
 Another study examined the effectiveness of bacteriophage KPP12 
against P. aeruginosa keratitis in mice. KPP12 was shown to have activity 
against a wide range of clinical isolates of P. aeruginosa and uses the lytic life 
cycle.50 The study used a single dose of KPP12 with MOI of 100 applied via eye 
drops directly onto the surface of the infected eyes. The eyes were examined 1, 
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3, and 5 days post phage administration. The control group had opacities spread 
across the cornea over the course of 5 days, and developed perforated 
corneas.50 The phage treated group had slight opacities on day 1, that improved 
over the course of 5 days.50 It was also determined that the KPP12 phage could 
be stored at 4°C for 1 month and retain activity.50 
  
 A study performed by Morello et al., investigated the efficacy of 
bacteriophages against a mucoid forming P. aeruginosa strain isolated from a 
cystic fibrosis patient, called CHA.51 The mice were dosed with CHA which 
induces death by 48 hours. There were 2 treatment groups, one was given P3-
CHA phages 4 days prior to infection, and the curative group was given P3-CHA 
phages 2 hours post infection. All phages were administered intranasally. The 
preventative treatment resulted in 100% survival for the 16 day duration of the 
experiment, while the curative treatment resulted in a 95% survival rate.51 Higher 
doses of active phage were better at promoting survival.51 It was also determined 
that phage therapy was not pro-inflammatory and cytokine production was not 
strongly stimulated as long as the phages selected did not have endotoxins.51 
Another study performed by infecting murine lungs with P. aeruginosa and 
administering a mixture of ϕMR299-2 and ϕNH-4 phages 2 hours post infection 
also showed promising results, reducing P. aeruginosa levels by 3-4 log in 6 
hours.52 In another study regarding lung infections, a bacteriophage, PAK-P1 
was isolated from sewage water and found to have activity against the PAK 
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strain of P. aeruginosa used in the experiment.53 PAK-P1 phage was applied 
intranasally at MOI of 0.1, 1, or 10 either 24 hours prior to infection, or 2 hours 
post infection. Results showed that 100% of the prophylactically treated mice 
survived the 12-day duration of the experiment.53 100% of the mice treated with 
the MOI of 10 in the curative treatment group survived the duration as well.53 
100% of the mice that were not treated died within 2 days.53 
 
 A study conducted using a mouse model for chronic lung infections 
caused by P. aeruginosa LESB65, a common strain in the Liverpool epidemic 
strains seen in cystic fibrosis.54 Mice were infected via inhalation. Once infections 
were established, a second ‘host adapted’ strain, called NP22_2, was recovered 
from mice and reintroduced to a new group of mice. NP22_2 is better at 
simulation of chronic infections and establishes new lung infections more 
easily.54 The two strains were then treated with phage PELP20 in 3 treatment 
groups (Figure 8). Treatment 1 and 2 had the infection completely resolve, while 
treatment 3 had the infection resolve in 70% of mice, and the remaining 30% still 
had significant improvement.54  
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Figure 8. Phage Activity Against P. aeruginosa LESB65 and NP22_2.  
Log CFU per lung for each of the 3 treatments with phage PLEP20. Treatment 1 
and 2 used LESB65, while Treatment 3 used NP22_2. Treatment 1 had phage 
given at 24 and 36 hours post infection, CFU counted at 48 hours. Treatment 2 
had phage given at 48 and 60 hours post infection, CFU counted at 72 hours. 
Treatment 3 had phage given at 144 and 156 hours post infection, and CFU 
counted at 168 hours. All controls received phosphate-buffered saline. Figure 
adapted from Waters et al. 2017.54  
 
 One study tested the efficacy of phage therapy against P. aeruginosa 
PAO1 using phage PA1Ø in normal and neutropenic mice.55 A lethal dose of 
PAO1 was injected into the mice followed by a single dose of PA1Ø at MOI of 1, 
10, and 100.55 Survival rates in normal mice were found to be 80-100%, and no 
viable bacteria was found in organ samples 48 hours post treatment.55 However, 
in neutropenic mice the treatment was only effective in extending their life by 12 
hours.55 
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 Another study evaluated phages MPK1 and MPK6, these are lytic phages 
against the P. aeruginosa PAO1 strain.56 PAO1 was used to induce peritonitis-
sepsis in mice and phages were administered separately via intramuscular or 
intraperitoneal routes 6-12 hours post infection. Results show that treatment with 
MPK1 had 80% survival after 2 days in the intramuscular test group and 100% 
with intraperitoneal administration.56 The other phage, MPK6 had 20% survival 
via the intramuscular route and 70% with the intraperitoneal test group.56 Similar 
antibacterial efficacy of MPK1 and MPK6 was observed when used in a P. 
aeruginosa systemic-infection Drosophila melanogaster model, which means it 
may be possible to use as cheaper method of evaluating efficacy of phages.56 
 
 The efficacy of phage therapy with lytic phage KPP10 was determined for 
P. aeruginosa induced gut-derived sepsis in a murine model.57 108 PFU KPP10 
phage was administered orally and survival rates were recorded. Phage 
treatment groups are as follows: 1 day prior to infection, 1-day post infection, and 
6 days post infection.57 In the experimental group treated with phages 1-day post 
infection, 66.7% of mice survived the experiment while the other two 
experimental groups had similar results to the control group. which had 0% 
survival rate (Figure 9).57 The study also found that in phage treated mice, there 
were lower levels of inflammatory cytokines.57 
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In another study, dogs with chronic P. aeruginosa otitis were treated with 
single dose of 6-phage cocktail containing 1 x 105 PFU of each phage by direct 
application to the external auditory canal.58 By 48 hours post treatment, the 
calculated clinical score decreased by 30% and P. aeruginosa counts 
significantly decreased by 67%.58 
 
 
Figure 9. Survival Rate of Mice After KPP10 Treatment. Mice with gut-derived 
sepsis were treated with KPP10 phages orally. Group 1(Δ) was treated 1 day 
prior to infection. Group 2(□) was treated 1 day post infection. Group 3(○) was 
treated 6 days post infection. Figure adapted from Watanabe et al. 2007.57  
 
Human Studies 
In a study to evaluate the safety of orally administered bacteriophages, 15 
healthy adults were given T4 phage for Escherichia coli in drinking water for 2 
days.59 There were no adverse side effects directly related to phage 
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consumption, however it is to be noted that the T4 phage used was found to only 
lyse 2 of the 42 E.coli strains tested.59 Therefore, this was a test used to 
determine the safety of ingesting phages, but not including the lytic effects and 
subsequent immune response due to phage therapy.59 The results of this study 
regarding the safety of phages was similar to what has been documented by 
other researchers in Poland and the Soviet Union, that described few mild 
adverse side effects in people treated with phage therapy.26,30 
 
Humans trials are limited in number at this time. In a randomized, double 
blind, placebo-controlled Phase I/II clinical trial, a bacteriophage cocktail was 
used in an attempt to treat chronic otitis infections caused by antibiotic resistant 
P. aeruginosa and determine its safety.60 The patients in the phage treatment 
group were given a single dose of the phage cocktail. The results of the trial 
showed significant clinical improvement in the phage treated group, and no 
change in the control group (Figure 10).60 There were no reported side effects or 
toxicity, although it was a small study of 24 individuals.60 The study reported that 
3 of the cases of chronic otitis appeared to be cured through phage therapy. 
There was also a large difference in the amount of therapeutic agent 
administered. Compared to standard antibiotics which require many doses that 
total up to several grams, the single dose of phage cocktail used in this study 
was only 2.4 ng and achieved a positive outcome.60 The study also discovered 
that the mean phage replication period was 23 days, therefore providing insight 
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and future directions to determine how often, if at all, additional doses of phage 
therapy need to be administered.60 The authors of this study plan on further 
development of Biophage-PA, a 6-phage cocktail used here to treat other forms 
of PA infections such as burn sites or lung infections, however nothing has been 
released currently.60 
 
 
Figure 10. P. aeruginosa CFUs/g Counts After Phage Therapy.  
(a) The mean and (b) median CFUs/g count as a percentage of the initial CFUs/g 
in the test and control groups over the course of 42 days. Figure adapted from 
Wright et al. 2009.60  
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Synergy with Antibiotics 
 In a two part study done by Oechslin et al., efficacy of phage only and 
phage combination therapy with ciprofloxacin or meropenem was evaluated for 
treatment of P. aeruginosa experimental endocarditis in vitro and in vivo.61 The 
study used a PP1131 cocktail containing 12 phages. Clinical isolates of P. 
aeruginosa were tested, and 31/33 were susceptible to at least 2 phages in the 
PP1131 cocktail, and 2 strains were resistant to all 12 phages.61 The first portion 
utilized in vitro fibrin clots to simulate endocarditis vegetations, which are lesions 
that are formed of platelets, fibrin, and P. aeruginosa CHA or P7 colonies. It was 
determined that phage therapy with phage cocktail PP1131 managed to kill 7 log 
colony forming units (CFU) per gram of fibrin clots in 6 hours in the P. aeruginosa 
CHA strain, however phage resistant strains regrew after 24 hours (Figure 11).61 
However, this regrowth was prevented when using in combination with 
ciprofloxacin.61 On the other hand, P. aeruginosa PA7, known to have phage 
resistance showed minimal changes in CFUs.61 Next, they attempted to prevent 
development of phage-resistant subpopulations by using phage-antibiotic 
combination therapy, using ciprofloxacin and meropenem.61 They found that both 
antibiotics acted synergistically with PP1131, both managing to kill > 4 log CFU 
(Figure 12).61  
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 In the second portion of the study, rats with experimental endocarditis of 
the aorta were used and the lysis of vegetations was measured.61 Using a single 
dose, phage therapy killed 2.5 log CFU/g of vegetations in 6 hours, which was  
 
 
Figure 11. Phage cocktail PP1131 Activity Against PA7 and CHA in vitro. In 
vitro fibrin clots were inoculated with 108 CFU of either (A) P. aeruginosa PA7 or 
(B) P. aeruginosa CHA and then 108 PFUs of PP1131 was administered. 
Controls in the top row were left untreated, while controls in the bottom row had 
no P. aeruginosa. Figure adapted from Oechslin et al. 2017.61 
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determined to be comparable to ciprofloxacin monotherapy.61 However, when 
used in combination, lysis of >6 log CFU/g vegetation occurred in 6 hours and 
treated 64% of rats, compared to 0% in either monotherapy group.61 Both 
ciprofloxacin and meropenem acted synergistically with the phage treatment, and  
 
 
 
Figure 12. Phage/Antibiotic Synergy in P. aeruginosa. Measurement of the 
activity against P. aeruginosa for 2 combination therapies over the course of 24 
hours. Log CFU/mL were determined at times: 0 hours, 6 hours and 24 hours. 
108 PFUs/mL of PP1131 phage cocktail was combined with 2.5 minimal inhibitory 
concentration (MIC) of (A) ciprofloxacin(MIC of 0.19 µg/mL) or (B) meropenem 
(MIC of 0.125 µg/mL). ABT: Antibiotic. Figure adapted from Oechslin et al. 
2017.61  
 
CFU counts were lower after 24 hours compared to monotherapy of either 
antibiotics or phage therapy, where after an initial drop in CFU counts, rose by 
the 24 hour mark.61 Phage resistant bacteria were not present in vivo. The study 
also found a significant increase in cytokines IL-1β and IL-6 following phage 
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therapy, compared to that of ciprofloxacin treatments.61 Mutations conferring 
phage resistant come at a physiological cost to P. aeruginosa fitness, causing 
changes to two virulence factors; lipopolysaccharides on the outer membrane 
and the type IV pili.61 
 
 In another study, P. aeruginosa strain PA14 was used to create biofilms 
on plastic and onto nasopharyngeal human epithelial cells.62 The study tested the 
efficacy of two bacteriophages in combination with one of several antibiotics: 
ceftazidime, ciprofloxacin, colistin, gentamicin, and tobramycin. The study also 
investigated giving the antibiotics and phages simultaneously, or staggering the 
administration with phages first, followed by antibiotics later. The bacteriophages 
in this study had different mechanisms of infection, and there was found to be 
some synergy between the phages and antibiotics.62 Synergy is defined as 
having a greater effect together than what would be expected based on individual 
results. The results showed that there was some synergy in the simultaneous 
treatment group, occurring for: ceftazidime at 1 MIC and 8 MIC, and ciprofloxacin 
at 1 MIC.62 Combination therapy was facilitative for ciprofloxacin at 8 MIC and for 
tobramycin 1 MIC.62 No synergy or facilitation was determined for colistin and 
gentamicin.62 The study also found that at 8 MIC, gentamycin, tobramycin, and 
ciprofloxacin all suppressed phage replication, possibly due to killing the bacteria 
before the phages had sufficient time to go through the lytic cycle.62 
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Bacteriophages as a Surface Disinfectant 
 P. aeruginosa often form biofilms on medical equipment and surfaces. In a 
study done by Zhang and Hu, they used RNA bacteriophages isolated from 
wastewater to test efficacy at removing biofilms.63 Bacteriophages were purified 
by passing wastewater over nylon filters and combining the filtrate with P. 
aeruginosa on agar plates to amplify the anti-Pseudomonas bacteriophages. It 
was determined that increases in concentration had a significant effect on both 
preventing P. aeruginosa biofilm formation, as well as treating pre-existing 
biofilms, the higher dosage of phage tested at 4.0 x 107 PFU/mL prevented 75 ± 
8% of formation, while the treatment at 6x107 PFU/mL removed 75 ± 5% of the 
pre-existing biofilm.63 Even at high concentrations of phage, there was still 
growth of the biofilms which may be due to factors such as biofilm structure, 
phage-resistant bacteria, and metabolically inactive bacterial cells which will all 
limit the effectiveness of phages.63 
 
 The study also paired the phages with chlorine, which is currently a 
commonly used method to limit bacterial contamination.63 It was determined that 
at a phage concentration of 3x107 PFU/mL and free chlorine concentration of 
210mg/L, there was 94 ± 2% reduction of new biofilm formation, and 88 ± 6% 
removal of pre-existing biofilms (Figure 13).63 They suggest that the phages 
could successfully penetrate deep into the biofilm and increase cell lysis, and 
chlorine was able to increase the percentage of dead cells by reducing their  
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Figure 13. Comparison of Phage, Chlorine and Combination Treatment. 
Depicted are P. aeruginosa biofilms on a glass surface that were treated with P. 
aeruginosa phages at 1.9 x 108 PFU/mL on Day 0, and continuous chlorine 
treatment at 200mg/L. The combination trial began with phage treatment followed 
by chlorine treatment. Shiny surfaces are clear of biofilm. Figure adapted from 
Zhang and Hu 2013.63 
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viability, while having little to no effect on the viability of the phages.63 It is 
important to note that they did not control for concentrations of individual phages 
in the cocktail, and a different set of phages may be more or less effective in 
preventing and treating biofilms. However, this shows promise as a potential 
disinfectant for equipment and surfaces in hospitals and other locations 
commonly contaminated by biofilms.63 A transmission electron microscope image 
of P. aeruginosa biofilms being treated with phages, chlorine, and in combination 
is shown in (Figure 14). Chlorine causes cell membrane disruption, while phage 
treatment causes cell lysis, and they are more effective combined together.63 
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Figure 14. Transmission Electron Microscopy of P. aeruginosa. P. 
aeruginosa biofilms imaged after treatment. Images as follows: (a) control,  
(b) chlorine only treatment, (c) phage only treatment, (d) Phage-chlorine 
combination treatment. Figure adapted from Zhang and Hu 2013.63   
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DISCUSSION 
 
 With the alarming rate of bacterial pathogens developing resistance to 
antibiotic treatments and a bleak outlook for new antibiotics in the pipeline, it is 
time to investigate other therapeutic options.1 Interest in phage therapy is making 
a resurgence and there are hopes it can be effective in combatting antibiotic 
resistant and MDR bacterial pathogens. Pseudomonas aeruginosa is an ideal 
candidate for developing phage therapy, as it is regarded as one of the top 
threats to healthcare today due to its inherent antibiotic resistance and 
development of MDR strains, such as LES.5,44 Research and development in the 
West has slowly begun to reach the clinical trials phase in vivo and in humans 
and the outlook is favorable.  
  
 Studies have shown that the ideal bacteriophages for phage therapy of  
P. aeruginosa are lytic phages with dsDNA genomes. These phages are easily 
isolated from a multitude of sources, with sewage and waste water being where 
the most effective antipseudomonal phages are located.41 Aforementioned in 
vitro and in vivo studies all indicate that monophage therapy can reduce P. 
aeruginosa CFU counts in both planktonic cells and in biofilms in multiple types 
of infections such as lung infections, burn wounds, otitis, keratitis and 
endocarditis.48,50,51,53,61 However, even more effective is using a cocktail of 
several phages that have shown activity against P. aeruginosa and prevent the 
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issue of resistance developing.43,48,58 Some antibiotics have also shown synergy 
with phage therapy, performing better than expected and is another potential 
future therapy option.61,62 Importantly, phage therapy has also shown to be 
relatively safe in humans thus far, supporting results from previous studies 
conducted in the Soviet Union and Poland, possibly due to daily exposure to 
bacteriophages and the fact they do not infect human cells.26,30,59  
  
 Phage therapy is not limited to solely using phages to treat infections 
directly. As discussed earlier, phages can be potentially used in combination with 
chlorine to act as a surface disinfectant and thus prevent nosocomial infections.63 
Additionally, several of the described studies concluded that phage therapy was 
most effective when used prophylactically.49,53 However, this would be 
unreasonable for clinical treatment, because it would be impossible to determine 
if a patient would develop an infection by a specific strain of a pathogen. Instead, 
this could be important for sanitation in hospital settings, where P. aeruginosa is 
often responsible for healthcare associated infections. It is possible in the future 
that a cocktail of several phages for multiple pathogens can be combined for this 
sanitation method. Endolysins and holins are proteins produced by the phage 
allowing them to release from bacteria at the end of the lytic cycle.26 It may be 
possible to utilize purified endolysins and holins without phages to treat 
infections, or combine them with antibiotics.39 It is also suggested that 
engineered endolysin-deficient phages can be used to prevent bacterial cell lysis 
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and release of bacterial endotoxins.38 These would be unable to release new 
phages, but with an active holin, is still able to kill the bacteria, but would be 
required at a higher dosage because they are not self-propagating.38 
   
As noted by studies described here, pathogens lost their virulence and 
had increased susceptibility to antibiotics as they became resistant to 
bacteriophages.64 Another possible therapeutic approach for controlling the 
severity of infections, such as those found in cystic fibrosis, would be to use 
phages to encourage evolution into less virulent phage resistant strains to reduce 
the severity of infection before using antibiotics or a different cocktail of phages 
to eradicate it.35 Due to the P. aeruginosa lung infections being the most common 
cause of respiratory failure for cystic fibrosis, and the fact that over 80% of these 
patients have a chronic drug-resistant infection by the age of 19, this may be a 
viable option to increase therapeutic options.15,16  
 
 Although research thus far looks promising, there are still some issues 
with phage therapy that will need to be determined before it can see wide-usage 
in a clinical setting. Several studies bring up the possibility of phages causing the 
release of inflammatory cytokines and activating the host immune system.57,61 
The studies described earlier had varied results when they examined cytokine 
production; some reported phage therapy resulted in a decreased release of 
cytokines compared to that antibiotic treatments, while others found there to be 
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an increase.51,57,61 Other concerns include the host immune system creating 
antibodies to remove the bacteriophage from circulation, however it is unknown if 
this was an issue hindering any of the studies described above.65 Several more 
issues facing phage therapy are the isolation, purification, identification, 
administration route and long-term storage of phages. The study by Golshahi et 
al. found were able to store viable phages in an aerosolizeable dry powder for 3 
months at 4°C, but it is unknown whether other forms of prepared phages can 
remain viable for similar duration.45 
 
 Phage therapy looks promising as an alternative or supplementary form of 
treatment to antibiotics, but it will likely be some time before phage therapy sees 
wide spread use. Although ambitious, a database characterizing all currently 
known and newly discovered bacteriophages will be beneficial for choosing the 
appropriate bacteriophages for phage therapy. Important characterizations that 
should be included in the database for phage therapy include the following: 
Family, genome type, lytic vs lysogenic, host range, phage virulence, cytotoxicity, 
pyrogenicity, shelf life, latent period, and burst size.66,67 Once a bacteriophage 
database is established, it will be very beneficial to establish the clinical aspect of 
phage therapy. It would allow for easier selection of appropriate phages for 
treating any infection in which bacterial isolates are cultured or genotyped. It will 
also allow for easier selection of multiple phages to create a targeted cocktail to 
reduce to occurrence of phage resistance, or even target multiple pathogens at 
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once. The next step would be to determine the best route of administration and 
dosing. Studies discussed here determined the intraperitoneal route to be most 
effective in a murine burn model.48 However, topical application for otitis and 
keratitis also proved effective, as well as oral administration for gut-derived 
sepsis. 50,57,58,60 It may be possible that other routes of administration are more 
effective and were not tested in these studies. Dosages administered in the 
aforementioned studies were not uniform, and therefore a standardized dosing 
guide will need to be established as part of the database as well. For the next 
step, it will important to determine ways to extend the shelf life of the phages.  
  
 In future studies it will also be important in determining when it is 
appropriate to use phage therapy. Should it be reserved for antibiotic resistant 
pathogens? Multidrug resistant pathogens? Maybe in conjunction with 
antibiotics? Or perhaps used in place of antibiotics altogether? As of right now, it 
is uncertain which will be the recommended therapy in the future. It is also 
possible that with a better biological understanding, new custom phages can be 
engineered, with tailored host ranges and be better optimized for therapeutic use 
compared to those found in nature. Altogether, phage therapy looks to be a 
promising direction for the future of medicine to take in its fight to stay ahead of 
antibiotic-resistant and multidrug-resistant Pseudomonas aeruginosa, as well as 
other bacterial pathogens. 
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